title: Synthesis and SAR of Lehualide B: a marine-derived natural product with potent anti-multiple myeloma activity.
abstract: We report a concise and convergent laboratory synthesis of the rare marine natural product lehualide B that has led to the discovery that (1) this compound has low nanomolar activity against human multiple myeloma cells and (2) the anticancer effects of lehualide B and its analogues are selective (i.e., they are approximately 2-3 orders of magnitude less toxic to human breast cancer cells). Synthetic lehualide B is shown to be an effective inhibitor of complex I of the mitochondrial electron transport chain, with potency similar to that observed for the terrestrial natural products piericidin A1 and rotenone, an observation that led to the discovery that piericidin A1 is also selectively cytotoxic toward human multiple myeloma cells. Interestingly, synthetic derivatives of lehualide B that resemble verticipyrone (an established complex I inhibitor composed of a γ-pyrone and a simple monounsaturated hydrophobic chain) lack the potent antimyeloma activity of the natural product. Finally, the synthesis and evaluation of a collection of lehualide-inspired analogues led to the elucidation of structure-activity relationships for this rare natural product that established important roles for the substituted γ-pyrone headgroup and the skipped polyene side chain.
authors.affiliation: Departments of Chemistry, ‡Cancer Biology, and #Molecular Therapeutics, The Scripps Research Institute , Scripps Florida, Jupiter, Florida 33458, United States.
authors.forename: Valer
authors.initials: V
authors.lastname: Jeso
authors.forename: Chunying
authors.initials: C
authors.lastname: Yang
authors.forename: Michael D
authors.initials: MD
authors.lastname: Cameron
authors.forename: John L
authors.initials: JL
authors.lastname: Cleveland
authors.forename: Glenn C
authors.initials: GC
authors.lastname: Micalizio
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D001688:Biological Products / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D045744:Cell Line, Tumor; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D011753:Pyrones / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D001688:Biological Products; D011753:Pyrones; C553823:lehualide B
references.citation: Org Lett. 2001 Jan 25;3(2):247-50
references.pmid: 11430046
references.citation: Am J Physiol Cell Physiol. 2007 Jan;292(1):C125-36
references.pmid: 16971499
references.citation: J Nat Prod. 2005 Sep;68(9):1400-3
references.pmid: 16180823
references.citation: Nature. 2006 Oct 26;443(7114):904-5
references.pmid: 17066005
references.citation: Curr Protoc Immunol. 2001 May;Appendix 3:Appendix 3B
references.pmid: 18432654
references.citation: J Immunol Methods. 1983 Dec 16;65(1-2):55-63
references.pmid: 6606682
references.citation: J Antibiot (Tokyo). 2006 Dec;59(12):785-90
references.pmid: 17323645
references.citation: Cancer Chemother Pharmacol. 2010 May;66(1):129-40
references.pmid: 19779717
references.citation: J Antibiot (Tokyo). 2001 Jul;54(7):548-53
references.pmid: 11560372
references.citation: Angew Chem Int Ed Engl. 2005 Jul 18;44(29):4442-89
references.pmid: 15991198
references.citation: Chemistry. 2011 Jun 14;17(25):6964-72
references.pmid: 21557354
references.citation: Mar Drugs. 2010 Mar 31;8(4):1059-79
references.pmid: 20479967
references.citation: J Antibiot (Tokyo). 2007 May;60(5):321-4
references.pmid: 17551211
references.citation: J Antibiot (Tokyo). 2001 Jul;54(7):541-7
references.pmid: 11560371
references.citation: Angew Chem Int Ed Engl. 2010 May 10;49(21):3666-70
references.pmid: 20394088
references.citation: J Antibiot (Tokyo). 2002 Jan;55(1):71-7
references.pmid: 11918069
references.citation: J Antibiot (Tokyo). 1996 Oct;49(10):1052-5
references.pmid: 8968401
references.citation: J Am Chem Soc. 2010 Aug 25;132(33):11422-4
references.pmid: 20681603
references.citation: Chem Rev. 2011 Mar 9;111(3):1417-92
references.pmid: 21319862
references.citation: J Antibiot (Tokyo). 2000 Aug;53(8):844-7
references.pmid: 11079808
references.citation: J Antibiot (Tokyo). 1986 Jan;39(1):32-7
references.pmid: 3753969
references.citation: Nat Rev Clin Oncol. 2012 Feb 21;9(3):135-43
references.pmid: 22349016
references.citation: J Antibiot (Tokyo). 1996 Jul;49(7):697-9
references.pmid: 8784434
references.citation: Cancer Res. 1997 Aug 15;57(16):3424-8
references.pmid: 9270008
references.citation: J Antibiot (Tokyo). 1986 Jan;39(1):38-43
references.pmid: 3753970
references.citation: Chem Biol. 2000 Dec;7(12):979-92
references.pmid: 11137820
references.citation: Mol Med. 2000 Dec;6(12):1008-15
references.pmid: 11474117
references.citation: J Am Chem Soc. 2006 Sep 13;128(36):11799-807
references.pmid: 16953619
references.citation: J Nat Prod. 1998 May;61(5):677-80
references.pmid: 9599278
references.citation: Bioorg Med Chem. 2009 Mar 15;17(6):2304-9
references.pmid: 19042133
references.citation: J Am Chem Soc. 2007 Dec 12;129(49):15112-3
references.pmid: 18004854
references.citation: J Nat Prod. 2011 Apr 25;74(4):809-15
references.pmid: 21351759
references.citation: Biochem J. 1974 Mar;138(3):415-23
references.pmid: 4372992
references.citation: J Cell Physiol. 2008 Apr;215(1):243-50
references.pmid: 17941090
references.citation: Mol Cancer Ther. 2005 Feb;4(2):333-42
references.pmid: 15713904
references.citation: Bioorg Med Chem. 2010 May 15;18(10):3481-93
references.pmid: 20456960
references.citation: European J Org Chem. 2010 Jan;2010(3):391-409
references.pmid: 24634606
references.citation: Org Lett. 2007 Jan 4;9(1):65-7
references.pmid: 17192086